Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 312

1.

Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial.

Soubrier M, Puéchal X, Sibilia J, Mariette X, Meyer O, Combe B, Flipo RM, Mulleman D, Berenbaum F, Zarnitsky C, Schaeverbeke T, Fardellone P, Dougados M.

Rheumatology (Oxford). 2009 Nov;48(11):1429-34. doi: 10.1093/rheumatology/kep261. Epub 2009 Sep 9.

PMID:
19741011
[PubMed - indexed for MEDLINE]
Free Article
2.

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.

Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK.

Clin Ther. 2003 Jun;25(6):1700-21.

PMID:
12860493
[PubMed - indexed for MEDLINE]
3.
4.

Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis.

Barrera P, van der Maas A, van Ede AE, Kiemeney BA, Laan RF, van de Putte LB, van Riel PL.

Rheumatology (Oxford). 2002 Apr;41(4):430-9.

PMID:
11961174
[PubMed - indexed for MEDLINE]
Free Article
5.

Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study.

Takeuchi T, Yamanaka H, Ishiguro N, Miyasaka N, Mukai M, Matsubara T, Uchida S, Akama H, Kupper H, Arora V, Tanaka Y.

Ann Rheum Dis. 2014 Mar;73(3):536-43. doi: 10.1136/annrheumdis-2012-202433. Epub 2013 Jan 11.

PMID:
23316080
[PubMed - indexed for MEDLINE]
Free Article
6.
7.

Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER.

van der Heijde D, Breedveld FC, Kavanaugh A, Keystone EC, Landewé R, Patra K, Pangan AL.

J Rheumatol. 2010 Nov;37(11):2237-46. doi: 10.3899/jrheum.100208. Epub 2010 Oct 1.

PMID:
20889601
[PubMed - indexed for MEDLINE]
Free Article
8.

Adalimumab and methotrexate is more effective than adalimumab alone in patients with established rheumatoid arthritis: results from a 6-month longitudinal, observational, multicentre study.

Heiberg MS, Rødevand E, Mikkelsen K, Kaufmann C, Didriksen A, Mowinckel P, Kvien TK.

Ann Rheum Dis. 2006 Oct;65(10):1379-83. Epub 2006 May 5.

PMID:
16679432
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial.

O'Dell JR, Curtis JR, Mikuls TR, Cofield SS, Bridges SL Jr, Ranganath VK, Moreland LW; TEAR Trial Investigators.

Arthritis Rheum. 2013 Aug;65(8):1985-94. doi: 10.1002/art.38012.

PMID:
23686414
[PubMed - indexed for MEDLINE]
10.

Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study.

Detert J, Bastian H, Listing J, Weiß A, Wassenberg S, Liebhaber A, Rockwitz K, Alten R, Krüger K, Rau R, Simon C, Gremmelsbacher E, Braun T, Marsmann B, Höhne-Zimmer V, Egerer K, Buttgereit F, Burmester GR.

Ann Rheum Dis. 2013 Jun;72(6):844-50. doi: 10.1136/annrheumdis-2012-201612. Epub 2012 Jun 27.

PMID:
22739990
[PubMed - indexed for MEDLINE]
11.

Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients.

Aletaha D, Funovits J, Keystone EC, Smolen JS.

Arthritis Rheum. 2007 Oct;56(10):3226-35.

PMID:
17907167
[PubMed - indexed for MEDLINE]
Free Article
12.

Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial.

Yamanaka H, Ishiguro N, Takeuchi T, Miyasaka N, Mukai M, Matsubara T, Uchida S, Akama H, Kupper H, Arora V, Tanaka Y.

Rheumatology (Oxford). 2014 May;53(5):904-13. doi: 10.1093/rheumatology/ket465. Epub 2014 Jan 17.

PMID:
24441150
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.

Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, Bridges SL Jr, Zhang J, McVie T, Howard G, van der Heijde D, Cofield SS; TEAR Investigators.

Arthritis Rheum. 2012 Sep;64(9):2824-35. doi: 10.1002/art.34498.

PMID:
22508468
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis.

Chen DY, Chou SJ, Hsieh TY, Chen YH, Chen HH, Hsieh CW, Lan JL.

J Formos Med Assoc. 2009 Apr;108(4):310-9. doi: 10.1016/S0929-6646(09)60071-1.

PMID:
19369178
[PubMed - indexed for MEDLINE]
15.

Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.

Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, Breedveld FC, Furst DE, Lipsky PE; ATTRACT Study Group.

Arthritis Rheum. 2005 Apr;52(4):1020-30.

PMID:
15818697
[PubMed - indexed for MEDLINE]
Free Article
16.

Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis.

Emery P, Genovese MC, van Vollenhoven R, Sharp JT, Patra K, Sasso EH.

J Rheumatol. 2009 Jul;36(7):1429-41. doi: 10.3899/jrheum.081018. Epub 2009 Apr 15. Erratum in: J Rheumatol. 2010 May;37(5):1081. J Rheumatol. 2010 Oct;37(10):2198.

PMID:
19369462
[PubMed - indexed for MEDLINE]
17.

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial.

Smolen JS, Emery P, Fleischmann R, van Vollenhoven RF, Pavelka K, Durez P, Guérette B, Kupper H, Redden L, Arora V, Kavanaugh A.

Lancet. 2014 Jan 25;383(9914):321-32. doi: 10.1016/S0140-6736(13)61751-1. Epub 2013 Oct 26. Erratum in: Lancet. 2014 Jan 25;383(9914):308.

PMID:
24168956
[PubMed - indexed for MEDLINE]
18.

Clinical consequences of delayed addition of adalimumab to methotrexate therapy over 5 years in patients with rheumatoid arthritis.

Keystone EC, Kavanaugh A, Weinblatt ME, Patra K, Pangan AL.

J Rheumatol. 2011 May;38(5):855-62. doi: 10.3899/jrheum.100752. Epub 2011 Feb 1.

PMID:
21285171
[PubMed - indexed for MEDLINE]
Free Article
19.

Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.

Wells AF, Westhovens R, Reed DM, Fanti L, Becker JC, Covucci A, Keystone EC.

J Rheumatol. 2011 Nov;38(11):2362-8. doi: 10.3899/jrheum.110054. Epub 2011 Sep 1.

PMID:
21885491
[PubMed - indexed for MEDLINE]
Free Article
20.

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.

St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, Keystone E, Schiff M, Kalden JR, Wang B, Dewoody K, Weiss R, Baker D; Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group.

Arthritis Rheum. 2004 Nov;50(11):3432-43.

PMID:
15529377
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk